Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (currently amended): A compound of formula I,

wherein

W is O or S;

X is NR₈;

Y is CR₉R₁₀-(CH₂)_n wherein

R₉ and R₁₀ are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or

Y is SO₂;

 R_1 is aryl;

R₂ is a mono- or bicyclic heteroaryl group comprising one two or more ring nitrogen atoms with the exception that R₂ cannot represent 2-phthalimidyl, and in case of Y = SO₂ cannot represent 2,1,3 benzothiadiazol 4 yl;

any of R_3 , R_4 , R_5 and R_6 , independently of the other, is H or a substituent other than hydrogen; and R_7 and R_8 , independently of each other, are H or lower alkyl;

with the exception of the compound of formula I wherein W is O, X is NR₈, Y is CH₂, R₁ is 4 chlorophenyl, R₂ is 2 pyridyl, R₃, R₄, R₅, R₇ and R₈ are each H and R₆ is chloro; or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended): A compound of formula I according to claim 5,

wherein

W is O or S;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is hydrogen or lower alkyl, and

n is an integer of from and including 0 to and including 3; or

Y is SO_2 ;

 R_1 is aryl;

 R_2 is a mono- or bicyclic-heteroaryl group comprising one-two or more ring nitrogen atoms-with the exception that R_2 cannot represent 2 phthalimidyl, and in case of Y = SO_2 cannot represent 2,1,3-benzothiadiazol 4 yl;

any of R_3 , R_4 , R_5 and R_6 , independently of the other, is H or a substituent other than hydrogen; and R_7 and R_8 , independently of each other, are H or lower alkyl;

with the exception of the compound of formula I wherein W is O, X is NR₈, Y is CH₂, R₁ is 4-chlorophenyl, R₂ is 2 pyridyl, R₃, R₄, R₅, R₇ and R₈ are each H and R₆ is chloro; or a salt thereof.

Claim 7 (currently amended): A compound of formula I according to claim 5,

wherein

W is O or S;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein

R₉ is H or lower alkyl, and

n is 0 to 3; or

Y is SO₂;

R₁ is phenyl that is unsubstituted or substituted by up to three substituents selected from amino, mono- or disubstituted amino wherein the substituents are selected independently from lower alkyl, hydroxy-lower alkyl, phenyl-lower alkyl, lower alkanoyl, benzoyl and substituted benzoyl wherein the phenyl

radical is substituted by one or two substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower-alkoxycarbonyl, lower alkanoyl and carbamoyl, and phenyl-lower alkoxycarbonyl wherein the phenyl radical radical is substituted by one or two substituents selected from nitro, amino, halogen, N-lower alkylamino, N,Ndi-lower alkylamino, hydroxy, cyano, carboxy, lower-alkoxycarbonyl, lower alkanoyl and carbamoyl; lower alkyl; substituted lower alkyl where up to three substituents are present independently selected from the group containing halogen, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl and phenyl-lower alkoxycarbonyl; hydroxy, lower alkoxy; phenyl-lower alkoxy; phenyloxy; halogen-lower alkoxy, lower alkanoyloxy; benzoyloxy; lower alkoxycarbonyloxy; phenyl-lower alkoxycarbonyloxy; nitro; cyano; carboxy; lower alkoxycarbonyl; phenyl-lower alkoxycarbonyl; phenyloxycarbonyl; lower alkylcarbonyl; carbamoyl; N-mono- or N,N-disubstituted carbamoyl that is substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl and hydroxy-lower alkyl, at the terminal nitrogen atom; amidino; guanidino; mercapto; sulfo; lower alkylthio; phenylthio; phenyl-lower alkylthio; lower alkylphenylthio; lower alkylsulfinyl; phenylsulfinyl; phenyl-lower alkylsulfinyl; lower alkylphenylsulfinyl; lower alkanesulfonyl; phenylsulfonyl; phenyl-lower alkylsulfonyl; lower alkylphenylsulfonyl; lower alkenyl; lower alkanoyl; halogen-lower alkylmercapto; halogen-lower alkylsulfonyl; dihydroxybora (-B(OH)₂); and lower alkylene dioxy bound at adjacent C-atoms of the ring;

R₂ is imidazolyl, quinolyl, naphthyridinyl, or a moiety of the formula Ib or Ic

$$A = B$$

$$N \qquad \qquad A = B$$

$$D \qquad \qquad D \qquad \qquad N - E \qquad Q),$$

$$N - E \qquad Q),$$

$$N - E \qquad Q)$$

wherein

r is 0 to 2;

A, B, D, and E are, independently of one another, N or CH, with the stipulation that not more than 2 of these radicals are N; preferably; and

Q is lower alkyl, hydroxy, lower alkoxy, lower thioalkyl or halogen; any of R₃, R₄, R₅ and R₆, independently of the other, is H, fluorine or lower alkyl; and R₇ and R₈, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 8 (currently amended): A compound of formula I according to claim 5, wherein W is O;

X is NR₈;
Y is CHR₉-(CH₂)_n wherein
R₉ is H or methyl, and
n is 0;

or Y is SO2;

R₁ is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl which is in each case either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; lower alkoxy; hydroxy; phenyl; phenoxy; halogen-lower alkoxy; halogen-lower alkyl; lower alkoxycarbonyl; N-lower alkyl carbamoyl; lower alkylsulfinyl; lower alkanesulfonyl; and lower alkoxycarbonyl lower alkyl;

 R_2 is imidazolyl, quinolyl, naphthyridinyl, 2 methyl pyridin 4 yl, 3 pyridyl or 4 pyridyl; any of R_3 , R_4 , R_5 and R_6 , independently of the other, are H, methyl or chloro; or

R₃ and R₄ together represent methylene dioxy and R₅ and R₆, independently of the other, are H, methyl or chloro; and

R₇ and R₈, independently of each other, are H, fluorine or methyl; or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A compound of formula I according to claim 5, wherein

W is O;

X is NR₈;

Y is CHR₉-(CH₂)_n wherein R₉ is H or methyl, and

n is 0;

or Y is SO₂;

R₁ is phenyl which is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; halogen-lower alkyl; lower alkylsulfinyl; and lower alkanesulfonyl;

 R_2 is imidazolyl, quinolyl, naphthyridinyl, 2 methyl-pyridin-4-yl, 3 pyridyl or 4-pyridyl; any of R_3 , R_4 , R_5 and R_6 , independently of the other, is H or methyl; and R_7 and R_8 , independently of each other, are H or methyl; or a N-oxide or a pharmaceutically acceptable salt thereof.

Claim 10 (currently amended): A compound of formula I according to claim 5, wherein

```
W is O;
X is NR<sub>8</sub>;
Y is CHR<sub>9</sub>-(CH<sub>2</sub>)<sub>n</sub> wherein
   R<sub>9</sub> is H or methyl, and
   n is 0;
or Y is SO2:
R<sub>1</sub> is phenyl which is either unsubstituted or independently substituted by one or two substituents selected
   from the group comprising halogen; lower alkyl; halogen-lower alkyl; lower alkylsulfinyl; and lower
   alkanesulfonyl;
R<sub>2</sub> is imidazolyl, quinolyl, 2 methyl pyridin 4 yl or 4 pyridyl;
any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H or methyl; and
R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or methyl;
or a salt thereof.
Claim 11 (canceled)
Claim 12 (canceled)
Claim 13 (currently amended): A compound of formula I according to claim 5 selected from
2 [(4-pyridyl)methyl]amino N [3-fluoro (4-trifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino-N-phenylbenzamide;
2-[(4-pyridyl)methyl]amino-N-[4-fluoro-3-(trifluoromethyl)phenyl]benzamide;
2 [(4-pyridyl)methyl]amino N [3-fluoro 5 (trifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino-N-[3,5 (bistrifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino-N-[3,4-bis-(trifluoromethyl)phenyl]benzamide;
2 [(4 pyridyl)methyl]amino N [3 methoxy 5 (trifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino N [3 (trifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino N [3 (1,1-dimethylethyl)phenyl]benzamide;
2 [(4-pyridyl)methyl]amino-N (3 cyanophenyl)benzamide;
2 [(4-pyridyl)methyl]amino-N [(3-methylthio)phenyl]benzamide;
2 [(4-pyridyl)methyl]amino N (3 acetylaminophenyl)benzamide;
```

2-[(4-pyridyl)methyl]amino N-[3-[(aminocarbonyl)amino]phenyl]benzamide;

2-[(4-pyridyl)methyl]amino N [3 (dimethylamino)phenyl]benzamide;

```
5-methoxy 2-[(4-pyridyl)methyl]amino N [3-(trifluoromethyl)phenyl]benzamide;
3-methyl-2-[(4-pyridyl)methyl]amino-N-[3 (trifluoromethyl)phenyl]benzamide;
4,5 difluoro 2 [(4-pyridyl)methyl]amino N-[3 (trifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino N' methyl N' [3 (trifluoromethyl)phenyl]benzamide;
2-[(4-pyridyl)methyl]amino N-[(3-methylsulphonyl)phenyl]benzamide;
2 [(4-pyridyl)methyl]amino-N-[(3-methylsulphinylphenyl]benzamide;
2-[(4-pyridyl)methyl]amino N [4-(1,1-dimethylethyl)phenyl]benzamide;
2 [(4 pyridyl)methyl]amino-N-(3 chlorophenyl)benzamide;
2-[(4-pyridyl)methyl]amino-N-(3-bromophenyl)benzamide;
2-[(4-pyridyl)methyl]amino N (3-methylphenyl)benzamide;
2-[(4-pyridyl)methyl]amino-N-(3-benzoylphenyl)benzamide;
2-[(4-pyridyl)methyl]amino N-[3-(aminocarbonyl)phenyl]benzamide;
2-[(3-pyridyl)methyl]amino N-[3-(trifluoromethyl)phenyl]benzamide;
2-[(4-quinolinyl)methyl]amino N-[3-(trifluoromethyl)phenyl]benzamide;
2-I(5-quinolinyl)methyl]amino-N-I3-(trifluoromethyl)phenyl]benzamide;
2-[(4-(2-methyl)pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;
2 [(4 (1,2 dihydro 2 oxo)pyridyl)methyl]amino N [3 (trifluoromethyl)phenyl] benzamide;
2 [(4 quinolinyl)methyl]amino N-(4 chlorophenyl)benzamide;
2-[(2-imidazolyl)methyl]amino-N-(4-chlorophenyl)benzamide;
2-[2-(4-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;
2-[2-(3-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;
2 [1-methyl-2-(3-pyridyl)ethyl]amino-N-[3 (trifluoromethyl)phenyl]benzamide;
2 [(1-oxido 4-pyridyl)methyl]amino N [3 (trifluoromethyl)phenyl]benzamide; and
2 [(4 pyridyl)methyl]methylamino N [3 (trifluoromethyl)phenyl]benzamide;
or a pharmaceutically acceptable salt thereof.
```

Claim 14 (canceled)

Claim 15 (canceled)

Claim 16 (currently amended): A pharmaceutical preparation, comprising a compound of formula I according to any one of claims 5 to 14 claim 5, or a N-oxide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.

Claim 17 (original): A process for the preparation of a compound of formula I according to claim 5, or a N-oxide or a pharmaceutically acceptable salt thereof, characterized in that

a) for the synthesis of a compound of the formula I wherein X represents NR₈, where R₈ is hydrogen and Y represents CHR₉-(CH₂)_n, each as indicated for a compound of formula I, and the remaining symbols W, R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are as defined for a compound of the formula I, an aniline derivative of the formula II

wherein W, R₁, R₃, R₄, R₅, R₆ and R₇ are as defined for a compound of the formula I, is reacted with a carbonyl compound of the formula III

$$R_2$$
-(CH₂)_n- C(R₉)=O (III)

wherein n, R₂ and R₉ are as defined for a compound of the formula I in the presence of a reducing agent; or

b) for the synthesis of a compound of the formula I wherein X is SO₂ and the remaining symbols R₁, R₂, R₃, R₄, R₅, R₆, R₇, W and X are as defined for a compound of the formula I, an aniline derivative of the formula II as defined under process variante a) is reacted with an acid of the formula IVa

$$R_2$$
-Y-OH (IVa)

or a reactive derivative thereof; or with a compound of formula IVb,

$$R_2$$
-Y-Hal' (IVb)

wherein Hal' is chloro, bromo or iodo; or

c) for the synthesis of compounds of the formula I wherein X represents NR_8 , Y represents CR_9R_{10} - $(CH_2)_n$ and the remaining symbols R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are as defined for a compound of the formula I, a halogen derivative of the formula V

$$\begin{array}{c|c}
R_{3} & W \\
R_{5} & R_{6}
\end{array}$$

$$\begin{array}{c|c}
R_{1} & (V) \\
R_{7} & R_{7}
\end{array}$$

wherein Hal represents iodine, bromine or chlorine and W, R₁, R₃, R₄, R₅, R₆ and R₇ are as defined for a compound of the formula I, is reacted with am amine of the formula VI

$$R_2$$
-(CH₂)_n- C(R₉)(R₁₀)-NHR₈ (VI)

wherein n, R₂, R₈, R₉ and R₁₀ are as defined for a compound of the formula I in the presence of an appropriate catalyst in an inert solvent in the presence of an aprotic base;

where the starting compounds defined in a), b) or c) may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;

any protecting groups in a protected derivative of a compound of the formula I are removed; and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.